L-Alanyl-L-seryl-L-threonyl-L-threonyl-L-threonyl-L-asparaginyl-L-tyrosyl-L-threonine compound with 2,2,2-trifluoroacetic acid (1:1)
别名
Peptide T TFA;((2S)-2-((2S,3R)-2-((2S,3R)-2-((S)-2-((S)-2-aminopropanamido)-3-hydroxypropanamido)-3-hydroxybutanamido)-3-hydroxybutanamido)-3-hydroxybutanoyl)-L-asparaginyl-L-tyrosyl-L-threonine compound with 2,2,2-trifluoroacetic acid (1:1)
Peptide T (TFA) is an octapeptide derived from the V2 region of HIV-1 gp120 and acts as a ligand for the CD4 receptor, blocking HIV binding to CD4. It inhibits viral entry in the MAGI cell assay and blocks infection in a luciferase reporter assay using HIV virions pseudotyped with the ADA envelope. Peptide T selectively inhibits HIV replication via the chemokine receptor CCR5 compared to CXCR4. At 10⁻⁸ M, it induces IL-10 production in human Th2 cell lines and peripheral blood mononuclear cells (PBMCs); at 10⁻⁹ M, it significantly inhibits IFN-γ production by PBMCs. However, subcutaneous administration of Peptide T at various doses and disease stages does not prevent or ameliorate experimental autoimmune encephalomyelitis (EAE) in vivo.